Angiogenesis and portal-systemic collaterals in portal hypertension
In patients with advanced liver disease with portal hypertension, portal-systemic collaterals contribute to circulatory disturbance, gastrointestinal hemorrhage, hepatic encephalopathy, ascites, hepatopulmonary syndrome and portopulmonary hypertension. Angiogenesis has a pivotal role in the formatio...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-05-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119306490 |
id |
doaj-de15144bcc61473c8cf6926a6089f3bb |
---|---|
record_format |
Article |
spelling |
doaj-de15144bcc61473c8cf6926a6089f3bb2021-06-09T05:51:45ZengElsevierAnnals of Hepatology1665-26812016-05-01153303313Angiogenesis and portal-systemic collaterals in portal hypertensionJuan Cristóbal Gana0Carolina A. Serrano1Simon C. Ling2Department of Pediatric Gastroenterology & Nutrition, Division of Pediatrics, Escuela de Medicina, Pontificia Universidad Católica de Chile. Chile; Correspondence and reprint request:Department of Pediatric Gastroenterology & Nutrition, Division of Pediatrics, Escuela de Medicina, Pontificia Universidad Católica de Chile. ChileDivision of Gastroenterology, Hepatology & Nutrition, Department of Paediatrics, University of Toronto, and The Hospital for Sick Children, Toronto, CanadaIn patients with advanced liver disease with portal hypertension, portal-systemic collaterals contribute to circulatory disturbance, gastrointestinal hemorrhage, hepatic encephalopathy, ascites, hepatopulmonary syndrome and portopulmonary hypertension. Angiogenesis has a pivotal role in the formation of portal-systemic shunts. Recent research has defined many of the mediators and mechanisms involved in this angiogenic process, linking the central roles of hepatic stellate cells and endothelial cells. Studies of animal models have demonstrated the potential therapeutic impact of drugs to inhibit angiogenesis in cirrhosis. For example, inhibition of VEGF reduces portal pressure, hyperdynamic splanchnic circulation, portosystemic collateralization and liver fibrosis. An improved understanding of the role of other angiogenic factors provides hope for a novel targeted therapy for portal hypertension with a tolerable adverse effect profile.http://www.sciencedirect.com/science/article/pii/S1665268119306490AngiogenesisPortal hypertensionVEGFSystemic collaterals |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Juan Cristóbal Gana Carolina A. Serrano Simon C. Ling |
spellingShingle |
Juan Cristóbal Gana Carolina A. Serrano Simon C. Ling Angiogenesis and portal-systemic collaterals in portal hypertension Annals of Hepatology Angiogenesis Portal hypertension VEGF Systemic collaterals |
author_facet |
Juan Cristóbal Gana Carolina A. Serrano Simon C. Ling |
author_sort |
Juan Cristóbal Gana |
title |
Angiogenesis and portal-systemic collaterals in portal hypertension |
title_short |
Angiogenesis and portal-systemic collaterals in portal hypertension |
title_full |
Angiogenesis and portal-systemic collaterals in portal hypertension |
title_fullStr |
Angiogenesis and portal-systemic collaterals in portal hypertension |
title_full_unstemmed |
Angiogenesis and portal-systemic collaterals in portal hypertension |
title_sort |
angiogenesis and portal-systemic collaterals in portal hypertension |
publisher |
Elsevier |
series |
Annals of Hepatology |
issn |
1665-2681 |
publishDate |
2016-05-01 |
description |
In patients with advanced liver disease with portal hypertension, portal-systemic collaterals contribute to circulatory disturbance, gastrointestinal hemorrhage, hepatic encephalopathy, ascites, hepatopulmonary syndrome and portopulmonary hypertension. Angiogenesis has a pivotal role in the formation of portal-systemic shunts. Recent research has defined many of the mediators and mechanisms involved in this angiogenic process, linking the central roles of hepatic stellate cells and endothelial cells. Studies of animal models have demonstrated the potential therapeutic impact of drugs to inhibit angiogenesis in cirrhosis. For example, inhibition of VEGF reduces portal pressure, hyperdynamic splanchnic circulation, portosystemic collateralization and liver fibrosis. An improved understanding of the role of other angiogenic factors provides hope for a novel targeted therapy for portal hypertension with a tolerable adverse effect profile. |
topic |
Angiogenesis Portal hypertension VEGF Systemic collaterals |
url |
http://www.sciencedirect.com/science/article/pii/S1665268119306490 |
work_keys_str_mv |
AT juancristobalgana angiogenesisandportalsystemiccollateralsinportalhypertension AT carolinaaserrano angiogenesisandportalsystemiccollateralsinportalhypertension AT simoncling angiogenesisandportalsystemiccollateralsinportalhypertension |
_version_ |
1721388991224217600 |